Cerus (CERS) AI Stock Analysis

• Market Cap: $370.89M
• Dividend Yield: N/A
• Average Volume (3M): 1.37M
• Price to Earnings (P/E): ―
• Beta (1Y): 1.74
• Revenue Growth: 13.03%
• EPS Growth: 21.28%
• Country: US
• Employees: 614
• Sector: Healthcare
• Sector Strength: 45
• Industry: Medical - Devices
• EPS (TTM): -0.01
• Shares Outstanding: 192,171,780
• 10 Day Avg. Volume: 2,156,919
• 30 Day Avg. Volume: 1,370,606
• PEG Ratio: 0.99
• Price to Book (P/B): 6.11
• Price to Sales (P/S): 1.90
• P/FCF Ratio: 46.07
• Enterprise Value/Market Cap: 1.21
• Enterprise Value/Revenue: 2.17
• Enterprise Value/Gross Profit: 3.99
• Enterprise Value/Ebitda: -59.19
• 1Y Price Target: $5.00
• Price Target Upside: 159.07% Upside
• Rating Consensus: Moderate Buy
• Number of Analyst Covering: 3
• EPS Forecast (FY): -0.04
• Revenue Forecast (FY): $250.00M

• Rating: 59 Neutral
• Price Target: $2.00 ▲(3.63% Upside)
• Action: Reiterated Date: 03/06/26
• Date: Action: Reiterated 03/06/26

The score is driven primarily by improving fundamentals (revenue growth, reduced losses, better leverage, and recently positive cash generation) and a constructive earnings outlook with reaffirmed 2026 growth and continued positive adjusted EBITDA. Offsetting factors are the lack of consistent GAAP profitability, margin and reimbursement-related uncertainties highlighted on the call, and only neutral technical momentum with the stock below key short-term moving averages.

Positive Factors

Recurring Consumable Revenue

Cerus’s business is anchored in recurring per-unit consumables (processing sets/kits) that scale with treated blood volumes. That model produces durable, predictable revenue tied to clinical throughput and creates high customer switching costs, supporting long‑term revenue visibility.

Improved Cash Generation & Lower Leverage

Leverage materially improved and operating/free cash flow turned positive in consecutive years, strengthening financial flexibility. This reduces refinancing risk, funds commercial investments and product launches internally, and improves the durability of growth funding without immediate dilution.

Strategic U.S. Distribution & Product Progress

A BCA group purchasing agreement opens streamlined contracting across ~50% of U.S. blood supply, lowering adoption friction and accelerating uptake of INTERCEPT kits. Coupled with recent CE Mark/commercial INT200 rollout, this creates structural pathways to expand recurring kit sales.

Negative Factors

Persistent GAAP Losses

Despite operational improvements, Cerus remains GAAP loss-making which keeps ROE negative and limits retained‑earnings compounding. Persistent GAAP losses constrain strategic optionality, can necessitate future capital raises, and reduce investor confidence in sustained profitability.

Gross Margin Pressure

Margins are under pressure from higher IFC production costs, import tariffs and inflation. Durable margin compression would erode free cash flow from recurring kit sales, reduce reinvestment capacity and make profitability more sensitive to price, mix and geopolitical cost shifts.

BARDA & Regulatory Timing Risks

The planned taper of BARDA‑reimbursed R&D revenue removes a significant near‑term revenue/R&D subsidy. Coupled with regulatory and timing uncertainty for RBC approvals and late‑2026 RedeS topline timing, this raises structural execution risk for larger addressable markets and cash‑flow timing.

Cerus Business Overview & Revenue Model

Company Description

Cerus Corporation operates as a biomedical products company. The company focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion. The company offers INTERCEPT Blood Systems for platelets and plasma, which is designed to inactivate blood-borne pathogens in platelets and plasma donated for transfusion; INTERCEPT Blood System for red blood cells to inactivate blood-borne pathogens in red blood cells donated for transfusion; and INTERCEPT Blood System for Cryoprecipitation that uses its plasma system to produce pathogen reduced cryoprecipitated fibrinogen complex for the treatment and control of bleeding, including massive hemorrhage associated with fibrinogen deficiency, as well as pathogen reduced plasma, cryoprecipitate reduced. It sells platelet and plasma systems through its direct sales force and distributors in the United States, Europe, the Commonwealth of Independent States, the Middle East, Latin America, and internationally. The company was incorporated in 1991 and is headquartered in Concord, California.

How the Company Makes Money

Cerus generates revenue primarily through the sale of its INTERCEPT Blood System and related products to blood banks, hospitals, and healthcare providers. The company earns income from direct sales of its systems and consumables, which are used in the pathogen reduction process. Additionally, Cerus may receive revenue from licensing agreements and collaborations with other companies in the healthcare sector. Significant partnerships with blood centers and regulatory approvals enhance its market presence and contribute to consistent earnings. The company also focuses on expanding its product offerings and market reach, which plays a crucial role in driving its revenue growth.

Cerus Financial Statement Overview

Summary

Strong multi-year revenue growth and stable mid-50% gross margins, with meaningful improvement in losses and leverage. Operating and free cash flow have been positive for two years, but GAAP profitability is not yet consistent and ROE remains negative, with cash-flow durability still being proven.

Income Statement

Revenue has scaled meaningfully over time (up from $91.9M in 2020 to $206.1M in 2025) and gross margin has remained solid and fairly stable around the mid‑50% range. Losses, however, persist, though profitability is improving: net margin narrowed from roughly -65% (2020) to about -7.6% (2025), and EBITDA losses have also tightened materially. The main weakness is that the business is still not consistently profitable, which keeps earnings quality and visibility below what investors typically want for the sector.

Balance Sheet

Leverage has improved notably, with total debt down to $56.4M in 2025 from about $96–98M in 2023–2024, and debt relative to equity improving to ~0.87x in 2025 (from ~1.75–1.82x in 2023–2024). Equity remains positive ($65.0M) and the asset base is stable-to-growing ($221.9M in 2025). The key weakness is that returns on equity remain negative due to ongoing net losses, which limits balance-sheet compounding despite the healthier capital structure.

Cash Flow

Cash generation has improved materially versus earlier years: operating cash flow and free cash flow were positive in 2024 and 2025 (operating cash flow of $11.4M and free cash flow of $8.5M in both years), a sharp reversal from large cash burn in 2020–2023. Free cash flow also compares favorably to the net loss (free cash flow running at ~75% of the net loss in 2024–2025), suggesting better working-capital and spending discipline. The primary risk is that cash flow consistency is still relatively new (after multiple years of negative cash flow), so durability through cycles remains to be proven.

Breakdown	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	206.13M	180.27M	156.37M	162.05M	130.86M
Gross Profit	112.29M	99.52M	86.40M	87.09M	67.38M
EBITDA	-13.43M	-10.02M	-26.34M	-33.52M	-45.99M
Net Income	-15.63M	-20.92M	-37.49M	-42.78M	-54.37M
Balance Sheet
Total Assets	221.86M	200.92M	197.75M	218.09M	237.50M
Cash, Cash Equivalents and Short-Term Investments	82.88M	80.45M	65.85M	102.15M	129.36M
Total Debt	96.95M	98.10M	96.00M	87.24M	87.59M
Total Liabilities	156.89M	144.02M	144.30M	149.53M	151.88M
Stockholders Equity	64.22M	56.15M	52.65M	67.61M	84.62M
Cash Flow
Free Cash Flow	8.52M	8.52M	-47.77M	-27.61M	-34.83M
Operating Cash Flow	11.36M	11.36M	-43.17M	-25.61M	-33.92M
Investing Cash Flow	-8.13M	-8.13M	8.62M	8.46M	12.69M
Financing Cash Flow	4.96M	4.96M	10.67M	4.19M	34.29M

Cerus Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 1.93
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Positive
• MACD: Positive
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For CERS, the sentiment is Negative. The current price of 1.93 is below the 20-day moving average (MA) of 2.31, below the 50-day MA of 2.30, and above the 200-day MA of 1.69, indicating a neutral trend. The MACD of -0.04 indicates Positive momentum. The RSI at 36.20 is Neutral, neither overbought nor oversold. The STOCH value of 23.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for CERS.

Cerus Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
BWAY	75 Outperform	$510.12M	45.75	11.05%	―	27.37%	269.84%
VMD	74 Outperform	$338.93M	19.35	10.94%	―	18.90%	29.22%
TCMD	61 Neutral	$646.47M	34.75	8.77%	―	9.28%	21.00%
CERS	59 Neutral	$370.89M	-25.12	-25.97%	―	13.03%	21.28%
Sector *	51 Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
OM	51 Neutral	$58.16M	-0.69	-106.20%	―	4.65%	68.71%
MASS	50 Neutral	$226.57M	9.76	-25.76%	―	4.49%	3.61%

Cerus Corporate Events

Cerus announces planned board transition as director departs

On January 19, 2026, Cerus Corporation announced that director Timothy L. Moore, whose current term runs until the company’s 2026 annual meeting of stockholders, has notified the board that he will not stand for re-election at that meeting. The company emphasized that Moore’s decision was not due to any disagreement regarding Cerus’s operations, policies or practices, suggesting the change reflects a routine board transition rather than signaling underlying strategic or governance disputes for investors or other stakeholders.

The most recent analyst rating on (CERS) stock is a Hold with a $2.50 price target. To see the full list of analyst forecasts on Cerus stock, see the CERS Stock Forecast page.